1 option
Pharmacoeconomic review report Tiotropium bromide monohydrate and olodaterol hydrochloride (Inspiolto respimat) for oral inhalation / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Economic development projects--Cost effectiveness.
- Economic development projects.
- Physical Description:
- 1 online resource (11 pages)
- Other Title:
- Pharmacoeconomic review report Tiotropium bromide monohydrate and olodaterol hydrochloride
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2015.
- Summary:
- Inspiolto Respimat (tiotropium bromide monohydrate/olodaterol hydrochloride [TIO/OLO]) is a fixeddose combination of a long-acting muscarinic antagonist (LAMA), tiotropium, and a long-acting beta2 agonist (LABA), olodaterol, indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. TIO/OLO is available as a multi-use cartridge to be used with the Respimat device, which provides 2.5 mcg of TIO and 2.5 mcg of OLO per actuation. The recommended dose of TIO/OLO is two actuations once daily.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.